MP-13.10 Prostate Cancer Focality and Selection of Patients for Focal Therapy

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S127-S128
Author(s):  
R. Giulianelli ◽  
L. Albanesi ◽  
F. Attisani ◽  
S. Brunori ◽  
B. Gentile ◽  
...  
2009 ◽  
Vol 181 (4S) ◽  
pp. 176-176 ◽  
Author(s):  
Markos Karavitakis ◽  
Hashim Uddin Ahmed ◽  
Naomi Livni ◽  
Ian Beckley ◽  
Matt Winkler ◽  
...  

2014 ◽  
Vol 13 (1) ◽  
pp. e357
Author(s):  
R-E. Berg ◽  
E. Rud ◽  
D. Klotz ◽  
E. Lundeby ◽  
K. Rennesund ◽  
...  

Author(s):  
James L. Liu ◽  
Hiten D. Patel ◽  
Nora M. Haney ◽  
Jonathan I. Epstein ◽  
Alan W. Partin

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 188-188
Author(s):  
Anthonius J. Breeuwsma ◽  
Maxim Rybalov ◽  
Anna Maria Leliveld ◽  
Rudi A. Dierckx ◽  
Jan Pruim ◽  
...  

188 Background: 11C-choline PET/CT has proven to be a sensitive technique for re-staging after radiation therapy (RT). The aim of this study was to analyze the clinical impact of 11C-choline-PET/CT in the selection of patients with biochemical recurrence (BCR) after RT for salvage cryoablation of the prostate. Methods: This prospective study was conducted between November 2006 and February 2012 on patients considered as candidates for salvage cryoablation. 74 patients, mean age 69.2 years, median – 70.3 years (range 49-79), who were being followed up after RT for histological proven prostate cancer (according to ASTRO-Phoenix) were included. Until 2009 we used PET/CT fusion, but from 2009 all patients were examined with an integrated PET/CT system. After receiving 400 MBq 11C-choline intravenously, a whole body scan was made. As reference we used biopsy-proven histology from site of suspicion, confirmative imaging modalities (bonescan, CT) or clinical follow-up. PSA doubling time and velocity was calculated. Results: According to the PET/CT results, 40 (54%) patients had a local recurrence, 20 (27%) had regional/distant metastases and 14 (19%) had a negative scan. The positive PET findings were proved by histology from prostate biopsies and/or pelvic lymph node dissections in 63% of cases. Considering PET/CT results: 50/74 (68%) patients received cryoablation, for 24/74 (32%) treatment was changed (active surveillance or androgen deprivation therapy). Conclusions: 11C-choline-PET/CT could be useful for the selection of patients with BCR after RT for salvage cryoablation of the prostate. 11C-choline-PET/CT was decisive and led to therapy change in 32% of cases. [Table: see text]


2013 ◽  
Vol 112 (4) ◽  
pp. E234-E242 ◽  
Author(s):  
Firas Abdollah ◽  
Nazareno Suardi ◽  
Umberto Capitanio ◽  
Andrea Gallina ◽  
Maxine Sun ◽  
...  

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 224-224
Author(s):  
Marc-Olivier Timsit ◽  
Giulia Baciarello ◽  
Christophe Hennequin ◽  
Francois Kleinclauss ◽  
Marie Laure Bazil ◽  
...  

224 Background: Multiparametric magnetic resonance imaging (mpMRI) detects ISUP grade≥ 2 prostate cancer (PC) with a sensitivity over 90%. mpMRI can be used for early detection in patients with a risk of clinically significant PC (csPC) either in combination with systematic biopsy (SB) to increase the detection rate of csPC, or to reduce the number of biopsy procedures by performing biopsies only in positive mpMRI patients. Methods: We estimated the numbers of PC diagnosed, PC deaths averted, and biopsy procedures performed with early diagnosis in a simulated population of men beginning at age 50 using a microsimulation model. The model simulates the natural history of PC and the impact of early diagnosis using epidemiological data from a systematic review of literature. Early diagnosis started at age 55 years, with a PSA threshold of 4 ng/mL. The strategies included (S1) SB alone, (S2) SB combined with mpMRI-targeted biopsy (SB/mpMRI-TB), and (S3) SB/mpMRI-TB following selection of patients based on positive mpMRI (PIRAD3-5) or PSA density (PSAd) < 0.15. A sensitivity of 0.92 and specificity of 0.48 for detecting ISUP grade ≥ 2 PC was used for mpMRI. Results: Compared to no early diagnosis, early diagnosis with SB alone (S1) was estimated to avoid 647 PC-related deaths per 100,000 men over their lifetimes. Using mpMRI was estimated to result in an additional 126 and 118 fewer deaths per 100,000 if mpMRI was used in conjunction with SB (S2) or with SB following patient selection for biopsy by mpMRI or PSAd (S3). To avoid a PC-related death was estimated to require screening of 145 men with SB alone, 121 with SB/mpMRI-TB, and 122 with mpMRI or PSAd followed by SB/mpMRI-TB. Adding mpMRI to SB was also found to reduce the predicted number of biopsies performed (21,821 for SB alone versus 16,510 for SB/mpMRI-TB and 15,385 for SB/mpMRI-TB following selection with mpMRI or PSAd). Conclusions: The results indicate that using mpMRI as a detection method will improve the effectiveness of early diagnosis. Compared to SB alone, using mpMRI through the SB/mpMRI-TB approach, with or without prior patient selection based on mpMRI or PSAd assessments, would result in a reduction in PC-related mortality and in the number of biopsies performed. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document